GlassScriptPhysician profile
Cindy Ung
NPI 1710305172
$6,158.88
in general payments reported to CMS, 2019-2025
19 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $1,727 · 2021: $364 · 2022: $660 · 2023: $850 · 2024: $705 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.11 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,750.09 | 2019-2020 | |
| Alcon Vision LLC | $897.23 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $823.66 | 2021-2024 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $806.34 | 2019 | |
| Genentech USA, INC. | $564.51 | 2021-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $352.79 | 2023-2024 | Syfovre |
| Astellas Pharma US INC | $162.45 | 2023-2025 | Izervay |
| Aerie Pharmaceuticals, INC. | $152.00 | 2021 | |
| Abbvie INC. | $139.06 | 2023-2024 | Ozurdex |
| Genentech, INC. | $131.13 | 2023 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $90.46 | 2022 | |
| Alimera Sciences, INC. | $89.53 | 2022-2024 | Yutiq, Iluvien |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Coherus Oncology, INC. | $27.85 | 2023 | |
| Amgen INC. | $26.23 | 2025 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $23.96 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.73 | 2024 | Acthar |
| Vyera Pharmaceuticals, LLC | $18.16 | 2022 | |
| Eyepoint US, INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Ung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.